The FDA has approved AstraZeneca and Alexion's gefurulimab (Klygefa), a once-weekly self-administered injectable nanobody targeting complement component 5 (C5) for adults with anti-AChR antibody-positive generalized myasthenia gravis. Approval follows the phase III PREVAIL trial involving 260 adults, which demonstrated significant functional improvements on the MG-ADL scale through 52 weeks. Gefurulimab joins competing C5 inhibitors eculizumab, ravulizumab, and zilucoplan, and carries a boxed warning for life-threatening Neisseria meningitidis infections managed under a REMS program requiring meningococcal vaccination compliance.
Story comments
Loading comments…